Presentation (CTI)

OBJECTIVES: A Joint Clinical Assessment (JCA) is built on the label a medicine is expected to receive — so what happens when that label changes mid-assessment? Prepared in parallel with European Medicines Agency (EMA) review, a JCA dossier can be partly or wholly voided by a late change to indication, population, posology, or contraindications. This study examined the operational and economic consequences of such changes and the adequacy of procedural safeguards.
METHODS: A procedural and policy analysis used Regulation (EU) 2021/2282, Commission Implementing Regulation (EU) 2024/1381 (including the provision governing changes to the therapeutic indication), EMA variation procedures, and published implementation analyses. Scenarios were modelled in which the regulatory object of the assessment is altered after the dossier is constructed, and the resulting rework, timeline, and cost implications were assessed.
RESULTS: The parallel design of JCA and EMA review creates a foreseeable, structurally recurring risk borne disproportionately by developers. Because the dossier is built on the anticipated label, a late indication change can require substantial re-analysis of PICOs, comparators, and subgroups within unchanged procedural timelines. Sunk costs per affected product were estimated in the low single-digit millions of euros. The framework currently lacks a clock-suspension mechanism keyed to material indication changes and a partial-adaptation route allowing unaffected dossier modules to be retained. The burden falls on an identifiable class of operators in circumstances they do not control — a pattern with potential implications under EU principles of legitimate expectation and equal treatment, though the question remains contestable.
CONCLUSIONS: A stop-the-clock mechanism for material label changes, paired with a right to reuse unaffected dossier modules, would spare developers avoidable rework and cost while protecting assessment quality and timelines.